WALTHAM, Mass., Nov. 8, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its third quarter 2021 financial results on Monday, November 15, after the close of the U.S. financial markets.
In connection with the earnings release, Syndax's management team will host a conference call and live audio webcast at 4:30 p.m. ET on Monday, November 15, to discuss the Company's financial results and provide a general business update.
The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website at www.syndax.com. Alternatively, the conference call may be accessed through the following:
Conference ID: 9558836Domestic Dial-in Number: (855) 251-6663International Dial-in Number: (281) 542-4259Live webcast: https://edge.media-server.com/mmc/p/85k2svad
For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website, www.syndax.com.
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn.
Syndax Contacts
Investor ContactMelissa ForstArgot Partnersmelissa@argotpartners.comTel 212.600.1902
Media ContactBenjamin Kolinskibenjamin.kolinski@gcihealth.comTel 862.368.4464
SNDX-G
View original content:https://www.prnewswire.com/news-releases/syndax-to-announce-third-quarter-2021-financial-results-and-host-conference-call-and-webcast-on-november-15-2021-301418269.html
SOURCE Syndax Pharmaceuticals, Inc.